{"contentid": 488061, "importid": NaN, "name": "Chief medical officer jumps ship in wake of bluebird trial stoppage", "introduction": "In a filing with the US Securities and Exchange Commission (SEC), bluebird bio has announced the departure of its chief medical officer, David Davidson.", "content": "<p><span style=\"font-weight: 400;\">In a </span><a href=\"https://www.sec.gov/ix?doc=/Archives/edgar/data/1293971/000129397121000023/blue-20210315.htm\"><span style=\"font-weight: 400;\">filing</span></a><span style=\"font-weight: 400;\"> with the US Securities and Exchange Commission (SEC), bluebird bio (Nasdaq: BLUE) has announced the departure of its chief medical officer, David Davidson.</span></p>\n<p><span style=\"font-weight: 400;\">The company said Dr Davidson would continue to be engaged as a consultant, &ldquo;for a period of six months,&rdquo; in order to provide &ldquo;ongoing guidance and support for bluebird&rsquo;s late-stage development programs in severe genetic disease.&rdquo;</span></p>\n<p><span style=\"font-weight: 400;\">The Boston-based firm saw its shares tumble in February, after a suspected serious adverse reaction put a stop to trials into an experimental LentiGlobin gene therapy for sickle cell disease.</span></p>\n<p><span style=\"font-weight: 400;\">The firm subsequently concluded the reaction was &ldquo;very unlikely&rdquo; to be linked to treatment, and will work with the US regulator to try to restart the program.</span></p>\n<p><span style=\"font-weight: 400;\">In its filing with the SEC, bluebird noted that the continued involvement of its former CMO on a consulting basis would be particularly important, &ldquo;as it navigates the regulatory interactions following the safety events,&rdquo; reported in February.</span></p>\n<p><span style=\"font-weight: 400;\">While a share in bluebird bio traded at around $45 in early February, news of the trial stoppage wiped out almost half of that value.</span></p>\n<p><span style=\"font-weight: 400;\">The firm&rsquo;s subsequent reassurances have begun to repair the damage, but investors will likely wait to hear from the US regulator before making up their minds.</span></p>\n<p><span style=\"font-weight: 400;\">The company has conducted its own investigations, and worked with independent experts to establish the cause of the suspected adverse reaction, a case of acute myeloid leukemia (AML).&nbsp;</span></p>\n<p><span style=\"font-weight: 400;\">Following this, bluebird said it initiated engagement with regulators to begin the process of resuming clinical studies in both sickle cell disease and &beta;-thalassemia.</span></p>\n<p><span style=\"font-weight: 400;\">Elsewhere,&nbsp;the European Medicines Agency&rsquo;s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) announced recently it would commence a safety review of the firm's medicine Zynteglo (betibeglogene autotemcel).</span></p>\n<p><span style=\"font-weight: 400;\">The medicine, a gene therapy for the rare blood condition beta thalassaemia, uses the same viral vector to deliver a gene into body cells.</span></p>", "date": "2021-03-17 10:43:00", "meta_title": NaN, "meta_keywords": "bluebird, medical, officer, chief, filing, Davidson, announced, February, reaction, firm, disease, gene, trial, stoppage, departure, Commission, Exchange", "meta_description": "In a filing with the US Securities and Exchange Commission (SEC), bluebird bio has announced the departure of its chief medical officer, David Davidson.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-17 10:38:32", "updated": "2021-03-17 11:44:34", "access": NaN, "url": "https://www.thepharmaletter.com/article/chief-medical-officer-jumps-ship-in-wake-of-bluebird-trial-stoppage", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "bluebird_bio_large.jpg", "image2id": "bluebird_bio_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Cell and Gene Therapy, Hematology", "topic_tag": "Boardroom, Management, Public health, Regulation, Research", "geography_tag": "USA", "company_tag": "bluebird bio", "drug_tag": "LentiGlobin, Zynteglo", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-17 10:43:00"}